Allegro Ophthalmics
As the chief operating officer from the inception of the company, focused on developing, communicating and executing on the business strategy based upon the discovery of a novel molecule to treat millions of patients at risk of blindness. Key contributions geared toward positioning the company for continued growth and maximizing its strategic options included:
- Creating the optimal corporate structure, including long-term planning by establishing a tax efficient international structure.
- Leading the marketing and communication strategy used with potential strategic partners, institutional investors and acquirers, as well as investment bankers, Wall Street analysts and the medical and scientific communities.
- Raising capital from alternative, minimally dilutive sources such as foundation grants and investments from private investors.
- Pursuing and securing international licensing and investment agreements in Japan, Korea and China that capitalized the company with more than $30 million and a 30x increase in valuation in less than four years, as well as diluting the founders’ equity stake by less than 25%.
- Overseeing all aspects of corporate finance and legal.
